The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Observational Cohort Studies in Rheumatic Diseases

류마티스 질환의 코호트 연구

  • Cho, Soo-Kyung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) ;
  • Kim, Dam (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) ;
  • Sung, Yoon-Kyoung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases)
  • 조수경 (한양대학교 류마티스병원 류마티스내과) ;
  • 김담 (한양대학교 류마티스병원 류마티스내과) ;
  • 성윤경 (한양대학교 류마티스병원 류마티스내과)
  • Published : 2014.11.01
⟨ Previous Next ⟩

Abstract

Rheumatic diseases are diverse groups characterized by a variety of clinical manifestations and disease courses in each patient. The best way to understand the course and prognosis of these patients is through observational cohort studies. The cohort studies also provide an opportunity to describe diseases outcomes including therapeutic responses and evaluate the effectiveness and safety of new therapy. It helps to understand disease pathogenesis and provide insight into the mechanisms of disease progression. The strengths of a cohort study are that it has a large number of patients over a long period of time. The patients in cohorts should be representative of the patients with diseases. Thoughtful study design and planning before establishment of cohorts will lead successful follow-up and increase data quality. The observation process must be clearly defined and followed according to the standard protocols.We reviewed numerous cohorts in rheumatic diseases and suggested the points to be considered for cohorts establishments.

Keywords

References

  1. Gladman DD, Farewell VT. Longitudinal cohort studies. J Rheumatol 2005;72:30-32.
  2. Goldacre M. The role of cohort studies in medical research. Pharmacoepidemiol Drug Saf 2001;10:5-11. https://doi.org/10.1002/pds.562
  3. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951;41:279-281. https://doi.org/10.2105/AJPH.41.3.279
  4. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J 1954;1:1451-1455. https://doi.org/10.1136/bmj.1.4877.1451
  5. Sherrer YS, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol 1987;14:705-709.
  6. Kremer J. The CORRONA database. Ann Rheum Dis 2005;64 Suppl 4:iv37-41.
  7. Curtis JR, Chen L, Bharat A, et al. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken) 2014 Jun 6[Epub]. http://dx.doi.org/10.1002/acr.22377.
  8. Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 2006;16:75-76. https://doi.org/10.3109/s10165-006-0464-8
  9. Yamanaka H, Inoue E, Singh G, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 2007;17:283-289. https://doi.org/10.3109/s10165-007-0587-6
  10. Iannaccone CK, Lee YC, Cui J, et al. Using genetic and clinical data to understand response to disease-modifying anti- rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 2011;50:40-46. https://doi.org/10.1093/rheumatology/keq263
  11. Desai SP, Liu CC, Tory H, et al. Rheumatoid arthritis quality measures and radiographic progression. Semin Arthritis Rheum 2014;44:9-13. https://doi.org/10.1016/j.semarthrit.2014.01.003
  12. Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013;9:e1003394. https://doi.org/10.1371/journal.pgen.1003394
  13. Sung YK, Cho SK, Choi CB, et al. Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. Semin Arthritis Rheum 2012;41:745-751. https://doi.org/10.1016/j.semarthrit.2011.09.007
  14. Kim D, Cho SK, Sung YK. The present and future of clinical research for Korean lupus patients. J Rheum Dis 2014;21:54-63. https://doi.org/10.4078/jrd.2014.21.2.54
  15. Petri M1, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-944. https://doi.org/10.1002/art.1780340802
  16. Oomatia A, Fang H, Petri M, Birnbaum J. Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period. Arthritis Rheumatol 2014;66:1000-1009. https://doi.org/10.1002/art.38302
  17. Gonzalez LA1, Pons-Estel GJ, Zhang J, et al. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus 2009;18:822-830. https://doi.org/10.1177/0961203309104392
  18. Pons-Estel GJ, Gonzalez LA, Zhang J, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) 2009;48:817-822. https://doi.org/10.1093/rheumatology/kep102
  19. Cervera R, Abarca-Costalago M, Abramovicz D, et al. Lessons from the "Euro-Lupus Cohort". Ann Med Interne 2002;153:530-536.
  20. Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009;18:869-874. https://doi.org/10.1177/0961203309106831
  21. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore) 2004;83:1-17. https://doi.org/10.1097/01.md.0000104742.42401.e2
  22. Shinjo SK, Bonfa E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010;62:855-862. https://doi.org/10.1002/art.27300
  23. Isenberg DA, Ramsey-Goldman R, Gladman D, Hanly JG. The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today. Lupus 2011;20:1426-1432. https://doi.org/10.1177/0961203311421501
  24. Reveille JD. A registry of ankylosing spondylitis registries and prospects for global interfacing. Curr Opin Rheumatol 2013;25:468-476. https://doi.org/10.1097/BOR.0b013e3283620e1d
  25. Almodóvar R, Font P, Zarco-Montejo P, et al. Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). Clin Exp Rheumatol 2011;29: 822-827.
  26. Gallinaro AL, Ventura C, Sampaio Barros PD, Goncalves CR. Spondyloarthritis: analysis of a Brazilian series compared with a large Ibero-America registry (RESPONDIA group). Rev Bras Reumatol 2010;50:581-589. https://doi.org/10.1590/S0482-50042010000500009
  27. Lee W, Reveille JD, Davis JC Jr, Learch TJ, Ward MM, Weisman MH. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007;66:633-638. https://doi.org/10.1136/ard.2006.060293
  28. Ward MM, Learch TJ, Gensler LS, Davis JC Jr, Reveille JD, Weisman MH. Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. Arthritis Care Res (Hoboken). 2013;65:257-265. https://doi.org/10.1002/acr.21821
  29. Lui NL, Haroon N, Carty A, et al. Effect of pregnancy on ankylosing spondylitis: a case-control study. J Rheumatol 2011; 38:2442-2444. https://doi.org/10.3899/jrheum.101174
  30. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-984.
  31. Maurer B, Graf N, Michel BA, et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 2014 Jun 30[Epub]. http://dx.doi.org/10.1136/annrheumdis-2014-205226.
  32. Silman A, Symmons D, Scott DG, Griffiths I, et al. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003;62:ii28-ii29.
  33. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2014 Mar 31 [Epub]. http://dx.doi.org/10.1136/annrheumdis-2013-204851.
  34. Kvien TK, Heiberg, Lie E, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(5 Suppl 39):S188-194.
  35. Lie E, Fagerli KM, Mikkelsen K, et al. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register. Ann Rheum Dis 2014;73:1905-1906. https://doi.org/10.1136/annrheumdis-2014-205490
  36. Askling J, Fored M, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-712. https://doi.org/10.1136/ard.2005.045872
  37. Arkema EV, Jonsson J, Baecklund E, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2014 Mar 7[Epub]. http://dx.doi.org/10.1136/annrheumdis-2013-204960.
  38. Komano Y, Tanaka M, Nanki T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Long term Safety. J Rheumatol 2011;38:1258-1264. https://doi.org/10.3899/jrheum.101009
  39. Sakai R, Tanaka M, Nanki T, et al. Drug retention rates and relevant risk factors for drug dis continuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012;71:1820-1826. https://doi.org/10.1136/annrheumdis-2011-200838
  40. Dixon WG, Carmona L, Finckh A, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69:1596-1602. https://doi.org/10.1136/ard.2009.125526

Cited by

  1. A paradigm shift in studies based on rheumatoid arthritis clinical registries vol.34, pp.5, 2014, https://doi.org/10.3904/kjim.2018.440